Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial

苯达莫司汀 奥比努图库单抗 医学 威尼斯人 慢性淋巴细胞白血病 揭穿 内科学 肿瘤科 氟达拉滨 进行性疾病 临床终点 胃肠病学 外科 临床试验 白血病 化疗 环磷酰胺 癌症 卵巢癌
作者
Paula Cramer,Moritz Fürstenau,Sandra Robrecht,Adam Giza,Can Zhang,Anna‐Maria Fink,Kirsten Fischer,Petra Langerbeins,Othman Al‐Sawaf,Eugen Tausch,Christof Schneider,Johannes Schetelig,Peter Dreger,Sebastian Böttcher,Karl‐Anton Kreuzer,Anke Schilhabel,Matthias Ritgen,Monika Brüggemann,Michael Kneba,Stephan Stilgenbauer
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:9 (10): e745-e755 被引量:14
标识
DOI:10.1016/s2352-3026(22)00211-3
摘要

Although BTK inhibitors provide long-term disease-control in patients with chronic lymphocytic leukaemia, they need to be combined with BCL2 inhibitors or antibodies to achieve deep responses with undetectable minimal residual disease (uMRD), which allows for time-limited treatment. This trial aims to evaluate the triple combination of obinutuzumab, acalabrutinib, and venetoclax after an optional debulking with bendamustine.This multicentre, open-label, investigator-initiated, phase 2 study evaluates a sequential treatment consisting of a debulking with two cycles of bendamustine for patients with a higher tumour load (70 mg/m2 intravenously on days 1 and 2, repeated after 28 days), followed by an induction and a maintenance with obinutuzumab (1000 mg intravenously on days 1-2, 8, and 15 of the first induction cycle, every 4 weeks in induction cycles 2-6 and every 12 weeks in the maintenance phase), acalabrutinib (100 mg orally twice daily continuously from induction cycle 2 day 1 onwards) and venetoclax (starting in induction cycle 3 with 20 mg per day with a weekly dose ramp-up over 5 weeks to the target dose of 400 mg per day). Eligible patients were aged 18 years or older with an ECOG performance score 0-2 and had relapsed or refractory chronic lymphocytic leukaemia requiring treatment according to the 2018 International Workshop on Chronic Lymphocytic Leukemia criteria. The primary endpoint was uMRD (<10-4) in peripheral blood at the end of induction treatment assessed centrally at the final restaging, 12 weeks after the start of the last induction cycle. As per protocol, all patients with more than two induction cycles were included in the analyses. This study is registered with ClinicalTrials.gov, number NCT03787264, and is ongoing.Between Jan 14, 2019, and June 25, 2020, 45 evaluable patients with relapsed or refractory chronic lymphocytic leukaemia were enrolled; 13 (29%) were female, 32 (71%) were male, 21 (47%) had already received a targeted agent, and 14 (32%) had del(17)(p13.1) or TP53 mutation. Ethnicity-race data was not collected. At data cutoff (Feb 25, 2021), all patients had completed the induction treatment. 34 patients (76%; 95% CI 61-87, p=0·26) had uMRD in peripheral blood after 6 months of triple therapy. Until data cutoff, 32 (71%) patients started maintenance and nine (28%) were able to stop with uMRD. After a median observation time of 13·8 months (IQR 10·4-18·4), there were two (4%) Richter transformations, but no progressions and no deaths observed. The most common adverse events of grade 3 and 4 during the entire treatment were thrombocytopenia and neutropenia (12 [27%] of 45 patients each), tumour lysis syndrome and infections (five [11%] of 45 patients each, grade 3 adverse events only), infusion-associated reactions (four [9%] of 45 patients) and anaemia (four [9%] of 45 patients).With 76% of patients achieving uMRD in peripheral blood, this trial did not reach the prespecified activity threshold. Triple therapy with obinutuzumab, acalabrutinib, and venetoclax after an optional debulking with bendamustine regimen requires further evaluation in larger trials to define its value compared with double treatment with a BTK or BCL2 inhibitor combined with obinutuzumab or a combination of the two oral targeted drugs. Until these trials show a clear benefit, the use of the triple combination in routine practice cannot be recommended.Acerta, AstraZeneca, F Hoffmann-La Roche, and AbbVie.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
mimi发布了新的文献求助10
1秒前
lwj发布了新的文献求助10
1秒前
2秒前
kalani发布了新的文献求助10
2秒前
搞怪的幻梅完成签到,获得积分10
2秒前
完美世界的应助被罗二狗采纳,获得10
2秒前
taoshiren发布了新的文献求助10
3秒前
Akim的应助被yjt采纳,获得10
3秒前
4秒前
4秒前
Hello的应助被FUTURE采纳,获得10
4秒前
Ffff发布了新的文献求助10
5秒前
zzy发布了新的文献求助10
5秒前
As故发布了新的文献求助10
5秒前
锦川完成签到,获得积分10
5秒前
烟花的应助被科研通管家采纳,获得10
6秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
6秒前
赘婿的应助被科研通管家采纳,获得10
6秒前
11点睡觉完成签到,获得积分20
6秒前
乐乐的应助被科研通管家采纳,获得10
6秒前
李爱国的应助被科研通管家采纳,获得10
7秒前
领导范儿的应助被科研通管家采纳,获得10
7秒前
Maestro_S的应助被科研通管家采纳,获得10
7秒前
CodeCraft的应助被科研通管家采纳,获得10
7秒前
今后的应助被科研通管家采纳,获得10
7秒前
CipherSage的应助被科研通管家采纳,获得10
7秒前
7秒前
深情安青的应助被科研通管家采纳,获得20
8秒前
深情安青的应助被科研通管家采纳,获得10
8秒前
彭于晏的应助被科研通管家采纳,获得10
8秒前
打打的应助被科研通管家采纳,获得10
8秒前
8秒前
8秒前
Dean的应助被科研通管家采纳,获得50
8秒前
爆米花的应助被科研通管家采纳,获得10
8秒前
Hiki完成签到,获得积分10
8秒前
Ava的应助被LI采纳,获得10
9秒前
风吹麦浪的应助被科研通管家采纳,获得10
9秒前
kelly发布了新的文献求助10
9秒前
Hello的应助被Xk采纳,获得10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189382
求助须知:如何正确求助?哪些是违规求助? 9576691
关于积分的说明 21849410
捐赠科研通 7787318
什么是DOI,文献DOI怎么找? 3435538
关于科研通互助平台的介绍 2559748
邀请新用户注册赠送积分活动 2482509